Identifying and validating a critical gene to treat Alzheimer’s disease using artificial intelligence

Alzheimer’s disease (AD) is the most common form of dementia and is projected to affect 600,000 Australians by 2030. Despite this, there are no therapies to treat AD and previous clinical trials have had a 99.6% failure rate. To address this, we will use artificial intelligence to identify a novel gene target based on genetic data from brains of patients with AD. We will then validate this gene as a target for gene therapy using an established mouse model of AD. Using this novel and innovative approach, we hope to identify a new, clinically relevant gene therapy treatment for AD.